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Currently available human tumour cell line panels consist of a small number of lines in each
lineage that generally fail to retain the phenotype of the original patient tumour. Here we
develop a cell culture medium that enables us to routinely establish cell lines from diverse
subtypes of human ovarian cancers with 495% efficiency. Importantly, the 25 new ovarian
tumour cell lines described here retain the genomic landscape, histopathology and molecular
features of the original tumours. Furthermore, the molecular profile and drug response of
these cell lines correlate with distinct groups of primary tumours with different outcomes.
Thus, tumour cell lines derived using this methodology represent a significantly improved
platform to study human tumour pathophysiology and response to therapy.
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M
ore than 60 years have passed since the establishment of
the first human cancer cell line, HeLa, in 1951 (ref. 1).
Since then, human tumour cell lines have had an
extremely important impact on cancer research and greatly
facilitated development of a variety of cancer treatments that
benefit human patients2–4.
Human carcinomas that grow uncontrollably in the body are
often paradoxically difficult to grow in cell culture. A robust and
efficient cell line model system that predicts patient response to
various drugs would greatly improve development and imple-
mentation of new drugs for personalized treatment of cancer
patients.
Despite many decades of improvements in methods for
establishing cancer cell lines3, it remains extremely difficult to
routinely establish high-quality, permanent cell lines from human
primary tumours with high efficiency, limiting the number and
diversity of cell lines available for study. Moreover, in many
tumour types, only high-grade subtypes have yielded cell lines,
resulting in collections that do not accurately reflect the true
spectrum of tumours encountered in the clinic.
Further, many of the tumour cell lines available are of
uncertain origin due to the lack of ‘fingerprinting’ technology
able to ascertain identity when the lines were developed. In
addition, the original tumour is not available for analysis with
modern technology such as next-generation sequencing. Thus, a
more efficient method of establishing human tumours as cultures
that reflect the heterogeneity of human tumours is highly
desirable and could offer a more effective platform for drug
discovery.
The challenges associated with establishing ovarian carcinoma
cell lines is illustrated by a comprehensive study, which reported
that only 11 out of 90 tumour samples could be established as cell
lines5. The 90 tumour samples were collected from 67 patients
with 44 serous, 2 clear-cell, 2 endometrioid, 3 mixed mullerian
and 16 not otherwise specified adenocarcinomas. All the
successful cell lines were from high-grade poorly differentiated
cancers with serous (n¼ 4), not otherwise specified (n¼ 4) or
mixed mullerian (n¼ 1) histology. Attempts to establish cell lines
from clear-cell and endometrioid cancers, or from moderately
differentiated carcinomas were not successful. Importantly, it
took 45 months for the first passage, and the cell lines could be
propagated only up to 15 passages5. In addition, all successful cell
lines were established from ascites fluid, not from solid tumours.
These limitations suggest a strong selection pressure in culture
that limits the ability of standard cancer cell line panels to
accurately reflect the diversity of human tumours. This has
caused some to question whether the tumour cell lines established
in routine culture media are truly representative of human clinical
tumours, and whether this limits their utility in understanding
tumour biology and facilitating drug development6,7.
The difficulty of establishing human tumour cell lines extends
to many other tumours types as well. For example, since the first
breast cancer cell line was established8, only a small number of
additional cell lines have been developed4. Cailleau et al.9
reported a 10% success rate from metastatic tumours, and 0%
for 300 primary tumours. Amadori et al.10 established only 1 cell
line out of 136 primary tumours. McCallum et al.11 established 10
cell lines out of 135 primary tumours. Gazdar et al.12 established
cell lines in 10% of the cases (18/177). However, all of these cell
lines had exceedingly long doubling times (16–60 days) and a
long lag time before the first cell passage (4–44 months), limiting
their usefulness12.
These experiences provide clear indication that the great
diversity of tumour subtypes and patient groups are not
adequately represented in the existing tumour cell line collections.
Consistent with this view, comparison of copy-number changes,
mutations and messenger RNA (mRNA) expression profiles
revealed pronounced differences between commonly used ovarian
cancer cell lines and ovarian cancer tumour samples13. Thus, not
only a very small fraction of human tumours can be cultured, but
these cell lines also appear to lose the characteristics of the
original tumour.
In general, the standard cell culture media such as DMEM,
Ham’s F12, Roswell Park Memorial Institute medium (RPMI),
McCoy’s and MCDB105 are composed of 40–50 ingredients.
Because they are unable to support living cells on their own, these
media are supplemented with tissue extracts, feeder layers, anti-
apoptotic drugs and serum. While these supplements have
improved culture results14,15, they also have various drawbacks.
At a minimum, the presence of anti-apoptotic drugs complicates
cytotoxic screens, tissue extracts introduce biological variability
and feeder layers may confound cytostatic assays.
Hence, we set out to develop a highly efficient culture system
that preserves the phenotype of the original tumour as much as
possible for common human cancers, driven both by the clear
need for improved in vitro models and by the encouraging results
with a chemically defined culture medium that we described
previously16. This medium has over 80 ingredients that provide
all the essential nutrients for maintaining basic cellular
metabolism without undefined supplements such as serum,
pituitary extract, feeder layers, conditioned medium or drugs16.
As a result, in this medium normal human breast epithelial cells
maintain telomerase activity17 and proliferate beyond 70
population doublings, a nearly 1021-fold expansion of cell
numbers, in contrast with the 10–15 doublings in the standard
medium16. More recently, we were also able to culture normal
ovarian and fallopian tube epithelium in a modified version of
this medium18. These results encouraged us to hypothesize that
perhaps human tumours could also be grown consistently in such
a medium.
Here, we report the phenotypic properties of 25 new ovarian
cancer cell lines (OCI) derived using cell culture media optimized
for human ovarian cancer subtypes (Ovarian Carcinoma
Modified Ince medium, OCMI). This panel of cell lines will be
available to the research community and nearly doubles the
number of existing 26 cell lines available from public cell lines
repositories, such as ATCC and ECACC.
Results
Tumour cells fail to thrive in standard cell culture media. In
standard culture media we were able to establish tumour cell lines
with a success rate of o1%, consistent with prior reports. In the
single successful case, the ovarian tumour line OCI-U1a is
derived in RPMI medium (Fig. 1a), in which a brief period of
rapid proliferation (days 0–20) is followed by growth arrest (days
20–40), widespread cell death (days 40–50) and the eventual
emergence of a rapidly proliferating rare clone that give rise to a
continuous cell line (days 60–90).
Importantly, the DNA copy-number variations (CNVs)
identified in the cell line that is established in RPMI differ
significantly from those found in the uncultured tumour tissue,
consistent with clonal outgrowth of select subpopulations or the
acquisition of additional genetic aberrations during tissue culture
(Fig. 1b). Consistent with the experience of others in this field,
this was the only tumour specimen that yielded a continuous
ovarian tumour cell line using standard media over the course of
our nearly 10-year-long study.
High-efficiency establishment of ovarian cell lines. To derive a
representative set of human ovarian cancer cell lines from
multiple types of ovarian tumours, we tested many culture
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conditions over 10 years and developed a medium (OCMI) that
allowed establishment of 25 new ovarian cancer cell lines in 26
attempts. Through a combination of theoretical deduction of
metabolic pathways and trial and error, we found a mixture of
variables with a large synergistic effect on culture efficiency16.
In many cases, the individual components had incremental
effects that emerged over many passages, varied between different
histotypes and patients and produced combined effects that were
non-obvious and synergistic, which made optimization difficult
(Supplementary Figs 1–4). Also, empirically testing all possible
combinations was prohibitive due to very large number of
permutations (Supplementary Note 1). Nevertheless, we were able
to find a formulation that has a high success rate across the
spectrum of ovarian tumours.
We refer to the ovarian carcinoma cell lines cultured in OCMI
medium as OCI lines, to distinguish them from standard ovarian
carcinoma (SOC) lines (Supplementary Tables 1 and 2). In OCMI
medium, the tumour cells are able to proliferate immediately
without significant in vitro clonal selection or a need to acquire
additional genomic or epigenetic aberrations (Fig. 1). Further-
more, it is possible to culture these cells continuously for
420–100 passages (B60–300 population doublings) with no
decrease in growth rate; we have not yet identified an upper limit
of population doublings (Fig. 1; Supplementary Table 3).
The capital letter after the ovarian carcinoma designation ‘OCI’
refers to the histological subtype of the original tumour: papillary
serous, clear cell, endometrioid and mucinous cancers, and rare
types such as carcinosarcoma and dysgerminoma. Together, the
papillary serous, clear cell, endometrioid and mucinous subtypes
account for 490% of ovarian adenocarcinomas; accordingly this
panel of cell lines is broadly representative of ovarian cancer. The
number after the histotype designation refers to the unique case
number.
The lower case letter at the end of each cell line name refers to
tissue source; 14 of the cell lines were established from primary
solid tumours, 7 from ascites fluid and 4 from primary mouse
xenografts derived from direct implantation of human tumours
into immunocompromised mice. All 25 OCI lines formed soft
agar colonies consistent with retention of a transformed
phenotype in culture (Supplementary Table 2). In two cases,
the bulk of the tumour was located in the fallopian tubes—these
cell lines are referred to as ‘FCI’ cell lines.
Adenocarcinoma of the ovary is a heterogeneous disease that is
comprised of many histopathological subtypes with distinct
features. In many cases, the original subtype of tumour that was
used to establish the ‘SOC’ cell lines is unknown13. Hence, in this
study we tried to use the small subset of SOC cell lines in which
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Figure 1 | Long-term culture of ovarian tumours in OCMI media. (a) Cells from malignant ascites fluid-containing ovarian carcinoma cells (OCI-U1a) were
plated in OCMI (blue line), MCDB105/M199 with 10% serum (green line) or RPMI-1640 with 10% serum (red line). A significant decrease in population
doubling is observed in MCDB105/M199 and RPMI-1640 media after 7 weeks (green and red lines). This was not observed in OCMI, in which the cells
reached 30 population doublings at cessation of the experiment. A fast proliferating cell population emerged in RPMI-1640 medium around day
90 (red line) and was established as a permanent cell line. (b) The whole-genome DNA copy-number variants (CNVs) of the OCI-U1a tumour cells
cultured in OCMI and RPMI and from the paired uncultured tissue were examined using a 250-K SNP array. The CNV trace reveals several peaks that are
gained (amplifications, black arrows) and lost (deletions, grey arrows) in tumour cells cultured in RPMI (top trace) compared with the uncultured tumour
sample (middle trace). In contrast, the CNV pattern of tumour cells cultured in OCMI appears significantly more similar to the uncultured tumour (bottom
and middle CNV traces, respectively). (c,d) The ovarian clear-cell lines OCI-C4p and OCI-C5x were cultured to at least 60 and 100 population doublings,
respectively, in OCMI (blue line). In the control medium (DMEM:F12 with 10% serum) the cells stopped proliferating in 30–40 days (red line). (e) Total cell
numbers were plotted instead of population doublings to highlight the scale difference in OCMI (blue line) versus DMEM:F12 with 10% serum (red line)
depicted in d. See Supplementary Methods, Supplementary Figs 1–6 and Supplementary Tables 1–7 for more detailed cell line and tumour information.
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Standard media fail to support OCI cell lines. We observed
that none of the OCI lines we tested can be efficiently
cultured in existing standard media (Supplementary Fig. 5a–d;
Supplementary Table 4). In contrast, all of the SOC lines
we tested can be cultured in OCMI medium (Supplementary
Fig. 5e–h).
The SOC lines are cultured in a variety of different standard
media, and no single standard medium appears to support culture
of all existing SOC lines, making it difficult to compare a large
panel of SOC lines with one another because they require
different media. Our results indicate that OCMI medium has the
potential to serve as a universal culture medium for SOC lines,
facilitating comparisons across cell lines.
We also observed that OCI cell lines cannot be efficiently
cultured in the medium recently described by Watanabe et al.,
who used an apoptosis inhibitor (Y-27632) that inactivates Rho-
associated kinase (ROCK) to help culture human embryonic stem
cells19,20. This medium was later used to culture several human
tumours14; however, our results indicate that Y-27632 has a
negative effect on OCI lines (Supplementary Fig. 6). Interestingly,
it was recently shown that the Y-27632 also negatively affects the
survival of CD34þ haematopoietic progenitor cells, human
adipose-derived stem cells and proliferation of melanomas21–23,
suggesting that it has differential impact on different lineages and
tissue-specific stem cells.
OCI cell lines mirror the genomic landscape of tumours. Major
genetic alterations may accumulate during cell culture in standard
media24. To compare tumour versus cell line genomes, we
examined their loss-of-heterozygosity (LOH) profiles and found
that the majority of OCI cell lines exhibit very high levels of
identity to their corresponding uncultured tumour sample
(Supplementary Figs 7 and 8). We had frozen primary tumour
samples available in 16 cases, which we used for the LOH
analysis. Among these, 14 cases have especially striking
similarities between the cell line and tumour with a 495%
identity between the LOH pattern of the uncultured tumour and
the matching cell lines (Supplementary Fig. 8; Supplementary
Data 1). In two cases, the similarity between the cell line and the
tumour is 90–95%. It is possible that intra-tumoral genetic
heterogeneity may be responsible for some of the small
differences between cultured cells and the primary tumour,
because the fragment of tumour from which the cell line was
established is necessarily different than the fragment of tumour
from which the DNA was isolated25–27. It is also possible that in a
few cases some of the changes may be due to accumulation of
genetic alterations during culture, even though there was no
noticeable difference in the growth rate among these lines and the
other OCI lines. In any case, there is a high overall match between
the LOH patterns of the primary tumours and OCI lines. We
were not able to compare the DNA of the SOC lines with the
matched original tumour DNA, because these cells were
established decades ago and the original tumour sample is not
available (Supplementary Table 1).
Next, we compared CNV patterns of OCI cell lines with the
ovarian tumours analysed in the TCGA data set28. Consistent
with the LOH analysis, we found that the overall CNV trends of
the OCI lines are similar to primary tumour samples
(Supplementary Fig. 9).
A persistent problem in the cell culture field has been cross-
contamination and misidentification of up to 15–20% of the cell
lines29. The close genomic match between OCI lines and the
original tumour tissues ensure that each OCI line is derived from
a unique patient. Furthermore, we sequenced the mitochondrial
DNA and short tandem repeats of the OCI and SOC lines to
provide a permanent unique identifier for authentication of these
cell lines (Supplementary Table 6). Overall, these results indicate
that OCI cell lines faithfully preserve the genetic alterations
present in the original tumour.
OCI and SOC lines have different mRNA signatures. Unsu-
pervised hierarchical clustering of the mRNA expression of 25
OCI and 6 SOC lines reveal two major clusters. There are 558
upregulated mRNAs in cluster 1 and 265 mRNAs in cluster 2
(Fig. 2; Supplementary Tables 8 and 9; Supplementary Data 2; see
GSE40788 for the complete data set).
Interestingly, mRNA cluster 1 contains only OCI lines and
most of the papillary serous lines (10/12) (Fig. 2). In contrast,
cluster 2 predominantly contains the non-serous lines (10/12),
and all of the SOC lines (6/6) (Fig. 2). Others have shown that
mRNA profiles of primary human serous cancers constitute a
distinct group, which is consistent with the above results30–32.
However, it was also observed that the gene expression profiles of
a subset of endometrioid and clear-cell cancers overlap with
papillary serous tumours in these analyses30–32. Reminiscent of
this pattern, we also observed that some of the endometrioid and
clear-cell OCI lines are in cluster 1 with the serous cell lines
(Fig. 2).
These results suggest that some of the tumours that are
histologically classified as endometrioid or clear-cell cancers may
have a papillary serous-like gene expression signature. In
summary, mRNA cluster 1 generally correlates with papillary
serous histology and OCI cell lines, and mRNA cluster 2
correlates with non-papillary serous histology and SOC cell lines.
To exclude medium-based differences, both OCI and SOC lines
were cultured in OCMI medium for these experiments.
In addition, SOC lines were cultured in standard versus OCMI
media in a control experiment. We observed that SOC lines
cluster next to each other regardless of whether they are cultured
in OCMI or in standard media (Fig. 2b).
These results indicate that the mRNA expression differences
observed between OCI versus SOC cell lines and between cluster
1 versus 2 are unlikely to be due to culture medium differences.
To uncover the pathways that are differentially expressed
between cluster 1 versus -2 cell lines, we used Ingenuity Pathway
Analysis (Supplementary Figs 10 and 11). This analysis revealed
that 37 pathways are upregulated in cluster 1, including NF-kB,
CXCR4, IGF-1, Rho-GDI, ILK, IL-6 and IL-8 signalling pathways
(Supplementary Table 10). The 41 pathways that are upregulated
in cluster 2 include Notch, BRCA, GADD45, Granzyme and
Stathmin signalling pathways (Supplementary Table 11; see
Supplementary Data 3 for the full list of pathways).
Protein and mRNA profiles identify the same OCI clusters. We
next used reverse-phase protein array (RPPA) to examine the
expression levels of 226 proteins in OCI and SOC cell lines. These
proteins were selected because they represent major signalling
pathways in cancer cells33. The unsupervised hierarchical
clustering of the protein expression data reveal two major
clusters that are nearly identical with the mRNA groups: the
RPPA cluster 1 contains only OCI lines as well as most of the
papillary serous lines (10/12) (Fig. 3). In contrast, RPPA cluster 2
predominantly contains the non-papillary serous lines (10/13),
and all of the SOC lines (6/6) (Fig. 3). See Supplementary Data 4
and 5 for the full list of RPPA antibodies and proteins
differentially expressed between clusters 1 versus 2.
It is worth noting that in the above experiments the mRNA
and protein extracts were prepared in triplicates from three
different passages in two separate experiments. Reassuringly, we
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observed that replicates from different experiments cluster
together (Supplementary Fig. 12; Supplementary Table 12).
Moreover, we confirmed that OCI lines maintain their
phenotype during long-term culture by comparing the RPPA
profile of 10 pairs of cell lines that were analysed at two different
times separated by 10–48 passages (Supplementary Fig. 13a).
Unsupervised hierarchical clustering based on the expression of
218 proteins demonstrate that the three replicates and two
different passages of each cell line cluster next to each other with
one exception that, nevertheless, remained in the same cluster
with a slight separation (Supplementary Fig. 13b,c). Furthermore,
comparison of the list of cell lines in mRNA versus RPPA clusters
reveal that they are identical with just one exception
(Supplementary Table 13). These results indicate that the
molecular differences between OCI versus SOC lines are stable
and reproducible across many passages and analytical platforms.
OCI cell line xenografts reproduce human tumour histology.
To examine the in vivo tumour phenotype of the OCI lines, we
injected each cell line into immunocompromised mouse hosts.
Ovarian carcinomas are characterized by very distinct
morphological features34 (Supplementary Fig. 14). These
differences in tumour morphology reflect relevant differences in
gene expression and clinical features31,32. However, recapitulating
architectural features of primary tumours has been an elusive goal
in most xenograft tumour models.
While it is difficult to entirely phenocopy a primary tumour in
a xenograft, we hoped to recapitulate some of the cardinal
features of different histotypes. For papillary serous carcinoma,
these morphologic features would include finger-like structures
(papillae) that consist of central stromal cores giving
rise to smaller branches lined by a malignant epithelium
with minimal cytoplasm and very large, high-grade, round
nuclei34 (Fig. 4a). In contrast, endometrioid adenocarcinoma—
named for its similarity to the endometrium—features
back-to-back glands that are organized around central lumina
surrounded by elongated malignant epithelial cells with abundant
cytoplasm34 (Fig. 4b). Another distinct subtype, clear-cell
carcinoma, typically forms microcysts, glands and/or papillae
that are lined with cells with abundant cytoplasm that
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Figure 2 | mRNA profiling of OCI cell lines identifies two major clusters. (a) Unsupervised hierarchical clustering of mRNA expression levels of OCI (blue
bars) and SOC (red bars) ovarian cancer cell lines reveal two clusters. Genes with Z2-fold difference relative to the median value in at least four cell lines
were selected for hierarchical clustering analysis (5,146 gene features). Rows represent individual genes and columns represent each cell line. The red and
green colours reflect relative high and low expression levels, respectively, as indicated in the scale bar (log2-transformed scale). Two major clusters are
observed: cluster 1 contains only OCI cell lines (left cluster, blue only), and cluster 2 contains a mixture of SOC and OCI cell lines (right cluster, red and
blue). While the papillary serous histotype almost exclusively align within cluster 1 (green bars), the other subtypes are present in both clusters (orange
bars). See Supplementary Methods, Supplementary Figs 10 and 11 and Supplementary Tables 8–11 for more detailed information. The complete mRNA
expression data set is available at Gene Expression Omnibus, GEO accession number GSE40788. (b) The dendogram of the cell lines that make up the two
clusters in the heatmap in a. The cell line names are coloured as follows; first column, OCI (blue) and SOC (red); second column, papillary serous (dark
green) and other histotypes (orange); third column, papillary serous (dark green), clear cell (light blue), endometrioid (pink), mucinous (light green) and
other histotypes (orange).
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Figure 3 | The proteomic profiling of OCI cell lines identifies two major clusters. (a) The unsupervised clustering of protein expression (measured by
RPPA) in OCI cell lines (blue bars) together with SOC ovarian cancer cell lines (red bars) reveal two distinct clusters. Rows represent cell lines and columns
represent antibody probes for each protein. The red and green colours reflect relative high and low expression levels, respectively. As in the mRNA
clustering, cluster 1 contains only OCI cell lines (top half of the heatmap, blue only), and cluster 2 contains a mixture of SOC and OCI cell lines (bottom half
of the heatmap, red and blue). While the papillary serous histotype almost exclusively aligns within cluster 1 (green bars), the non-papillary serous
subtypes (orange bars) are divided between cluster 1 and cluster 2. (b) The dendogram of the cell lines that make up the two clusters in a. The cell line
names are coloured as follows; papillary serous (green) and other histotypes (orange). See Supplementary Methods, Supplementary Figs 12–14,
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Figure 4 | Histopathology of OCI xenografts recapitulate the original human tumour. (a–c) Haematoxylin and eosin (H&E)-stained sections of primary
human tumours used to establish OCI-P8p (papillary serous), OCI-E1p (endometrioid) and OCI-C3x (clear cell) cell lines. (d–f) H&E-stained sections of
xenografts tumours derived by injecting SOC cells (ES2, SKOV3 and TOV-112D) subcutaneously into immunocompromised mice. The typical features of
human adenocarcinomas such as glands, papillae, stromal cores and desmoplastic stroma are absent. (g–o) H&E-stained sections of xenograft tumours
derived by injecting OCI cell lines (P5x, P7a, P9a, C5x, C3x, CSp and E1p) subcutaneously into immunocopromised mice. In papillary serous specimens,
note the presence of stromal cores and papillary architecture (g–i). In the endometrioid specimen note the presence of glands (m) which were positive for
oestrogen receptor (ER) and mucin (brown), respectively, consistent with the endometrioid phenotype (n,o). Scale bar, 100mM. See Supplementary Fig. 14
for additional images.
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cytoplasmic glycogen34 (Fig. 4c). Instead of glycogens, mucinous
cancers have high levels of mucin in their cytoplasm34
(Supplementary Fig. 5i).
In general, SOC lines produce poorly differentiated xenograft
tumours in mice, without any of the distinctive histopathologic
features of specific ovarian tumour subtypes (Fig. 4d–f).
In contrast, the OCI lines produce tumour xenografts
with a histopathology strongly resembling the original human
tumour (Fig. 4g–o). OCI-P5x, P7a and P9a were established
from human papillary serous carcinoma, and they recapitulate
the papillary serous-like-specific architecture in immuno-
compromised mice (Fig. 4g–i). The OCI-C3x and C5x lines
were established from human clear-cell tumours, and they form
microcysts and papillae lined by clear cells in mice (Fig. 4j,k).
The OCI-CSp line was established from a poorly differentiated
carcinosarcoma and it forms a poorly differentiated tumour in
mice (Fig. 4l). The OCI-E1p line was established from an
endometrioid adenocarcinoma and forms oestrogen receptor-
positive tumours with a glandular architecture, recapitulating the
original tumour phenotype (Fig. 4m–o).
In summary, quite remarkably, the OCI lines form tumours
that are morphologic phenocopies of corresponding human
ovarian carcinomas at the histopathologic level, unlike SOC lines,
which generally lack this characteristic.
The OCI lines recapitulate histotype-specific features of tumours.
Several molecular features help distinguish the histological
subtypes of human ovarian carcinomas35. High-grade serous
ovarian carcinomas (HGSOCs) are typically associated with high
frequency of p53 mutations, as well as elevated WT1 and p16
protein expression in 480% of the cases36–38. The low-grade serous
ovarian carcinomas are also WT1 positive; however, they tend to
lack p53 mutations and express low levels of p16 (refs 36–38). In
contrast, clear-cell ovarian carcinomas are associated with PI3K
mutations, high HNF1B and low/absent ARID1a expression36–39,
and they can be WT1 positive in B20% of the cases40.
The in vivo histotype-specific molecular features described
above are preserved to a great extent in OCI cell lines. On the
basis of an algorithm described previously36–38, it is not difficult
to place each OCI line into a specific ovarian cancer histotype
category (Table 1; Fig. 5; Supplementary Figs 16 and 17). In
contrast, SOC lines contain unusual features that are frequently
inconsistent with in vivo tumour histotypes.
Two of the SOC cell lines we examined—SKOV3 and A2780—
account for nearly 60% of ovarian carcinoma-related publications
according to a recent report13, and just 5 SOC lines account for
nearly 90% of published work13. While some of these SOC lines
have histotype-specific mutations such as in p53, PIK3Ca and
ARID1a (Table 1), their remaining profile is frequently at odds
with this mutational state. For example, the SOC lines ES2, OV90
and TOV-112 do not express high levels of WT1 and p16, despite
having p53 mutations (Table 1)38. Others have reported that only
5 of 32 SOC cell lines are WT1 positive, and of these only three
have mutant p53 (ref. 38). Hence, it appears that o10% of SOC
cell lines have HGSOC-like phenotype even though B70% of
malignant epithelial human ovarian cancers are HGSOCs13.
The putative cells of origin of ovarian cancer include the
normal ovarian surface, ovarian inclusion cysts and fallopian
tube epithelia that are almost uniformly cytokeratin-7 (CK7)
positive18,41. In addition, a majority of inclusion cysts and
fallopian tube epithelium and a minority of ovarian surface
epithelium are composed of CK7/PAX8 double-positive cells18.
This is a distinctive profile that helps distinguish normal ovarian
and fallopian tube epithelium from other tissues42,43. Consistent
with this, almost 90% of epithelial ovarian cancers are keratin 7
and/or PAX8 positive40,43 and 70% oestrogen receptor (ER)
positive44. Reassuringly, we found that the great majority OCI
lines we examined (86%) are also positive for ER, PAX8 and/or
CK7 as expected (Table 1).
Table 1 | The OCI cell lines retain histotype-specific features of ovarian tumours.
OCI Lines Mutation Protein expression Cell line phenotype
P53 PIK3CA Keratin 7 PAX8 ER WT1 p16 HNF1B
OCI-P5x Y236N WT þ þ þ þ þ þ þ þ þ þ High-grade serous
OCI-U1a V272M WT þ þ þ þ þ þ þ þ þ þ High-grade serous
OCI-P8p S127F WT þ þ þ þ þ þ þ þ þ þ High-grade serous
OCI-P2a R267G WT þ þ þ þ þ þ þ þ þ High-grade serous
FCI-P2p R248Q WT þ þ þ þ þ þ þ þ þ þ þ High-grade serous
OCI-P9a1 WT* WT þ þ þ þ þ þ þ þ þ þ C/w high-grade serous
OCI-P7a WT WT þ þ þ þ þ þ þ þ C/w high-grade serous
OCI-P1a WT WT þ þ þ þ þ þ þ Serous
OCI-E3x WT WT þ þ Endometrioid
OCI-E1p WT E545G þ þ þ þ þ Endometrioid
OCI-C1p WT Q546L, P539R þ þ þ þ þ þ þ þ þ þ þ þ Clear cell
OCI-C5x WT WT þ þ þ þ þ þ þ þ Clear cell
OCI-C4p 342STOP WT þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ Clear cell
OCI-C2p WT C420R þ þ þ þ þ þ Clear cell
Standard lines Pubmed citations
SKOV3 WT/null Mut þ þ þ þ þ þ þ 2,101
A2780 WT WT þ 1,363
ES2 S241F WT þ 128
OV90 S215R WT 43
TOV-112 R175H Mut
The protein expression for various histotype-specific proteins is examined with western blots in both OCI and SOC lines. The relative protein expression is represented from low (þ ) to high (þ þ þ ) in
the table. The corresponding western blot images are provided in the Supplementary Fig. 16. The OCI cell lines were examined for mutations in p53 (exons 3–9) and PI3K. The mutational profile of SOC
lines is from previously published reports38. The histotype that is most consistent with the combined mutational and protein marker profile is listed in the last column for each cell line. While p53
mutation in exons 3–9 is not detected, the xenograft tumours of OCI-P9a1 are strongly positive for both p53, p16 and WT1 immunostains, and OCI-P7a express high levels of p16 consistent. Therefore,
these cell lines are classified as potentially consistent with high-grade serous ovarian carcinoma (HGSOC)37,38. WT¼Wild Type and C/w¼Consistent with.
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In contrast, some SOC lines such as OV90 and TOOV-112 do
not express any of the ovarian-specific markers (Table 1) and
others express only one of three markers we examined (A2780
and ES2), raising some doubt about the differentiation state of
these lines.
mRNA profile of OCI lines correlates with patient outcomes.
Next, we compared the mRNA expression profile of the cell lines
with primary human tumours. Clustering analysis of the OCI and
SOC cell lines with 285 primary human ovarian tumour speci-
mens reveal two distinct patient clusters. Patient cluster 1 that
includes only OCI lines and patient cluster 2 that includes all of
the SOC lines (Fig. 6a). Complete data set available at Gene
Expression Omnibus (GEO) (GSE9899).
Significantly, the distribution of the cell lines within two
human tumour clusters is identical to the in vitro cell line mRNA
Clusters 1 and 2, with the exception of a single cell line (OCI-
C4p) (Supplementary Table 12). This result indicates that the
in vitro phenotype of the OCI cell lines generally conforms to
in vivo clinical tumour phenotypes. Furthermore, the comparison
of the clinical outcomes of these two groups reveal that the
patients who have OCI-like tumours (patient cluster 1) have a
worse progression-free and overall survival compared with
patients with SOC-like tumours (patient cluster 2) (Fig. 5b).
Drug response of OCI lines correlates with patient outcomes.
The striking difference between the outcome of OCI-like versus
SOC-like patient clusters prompted us to test whether the drug
response of the corresponding cell lines are different as well. To
test this, we treated OCI and SOC cell lines with taxol and cis-
platin, which are the two most commonly used first-line drugs for
the treatment of ovarian cancer.
In these experiments, we tested a subset of OCI and SOC lines
from mRNA/RPPA cluster 1 and cluster 2 that are representative
of a spectrum of different tumour subtypes (papillary serous, clear
cell, carcinosarcoma, endometrioid and mucinous), and tissue
sources (solid tumours, ascites fluid and xenograft explants)
(Supplementary Table 2). Finally, to exclude medium-based
differences, both OCI and SOC lines were cultured in OCMI
medium for these experiments.
Consistent with the worse outcome of patients in the OCI-like
cluster, we observe that the OCI lines in mRNA/RPPA cluster 1
are more resistant to taxol, cisplatin and vincristine compared
with SOC/OCI lines in mRNA/RPPA cluster 2 (Fig. 7a;
Supplementary Figs 19–21).
It is worth noting that there was at least 5–36 passages between
the RPPA analysis and taxol/cisplatin-sensitivity experiments
(Supplementary Table 13). Nevertheless, there was a close
concordance between RPPA clusters and drug response, provid-
ing additional evidence that the phenotype of OCI lines is stable
in culture. Moreover, these drug response experiments were also
carried out with equal number of serous, clear-cell and
endometrioid subtypes in each group (cluster 1 versus 2)
(Supplementary Table 14), indicating that the difference in drug
response is independent of histotype (Supplementary Fig. 20).
To explore the possible basis for the relative drug resistance of
OCI cells, we compared the protein profiles of cluster 1/OCI lines
with cluster 2/SOC lines (Fig. 7b), and found that drug-resistant
OCI lines in cluster 1 overexpress several proteins that have been
previously associated with taxol and cisplatin resistance including
tubulin (target of taxol), PAX2, Cox2, PAI1, AKT, PTEN,
SMAD3, caveolin and activated Erk (MAPKpT202)
(Supplementary Tables 14 and 15)45–51.
The drug-sensitive SOC lines in cluster 2 express higher levels
of several pro-apoptotic proteins, for example, Bim, SMAC-
DIABLO, cleaved caspase 7 and lower levels of inactive
phosphorylated BAD (pS112), a BH3-only pro-apoptotic protein.
High Bim levels have been inversely correlated with activated Erk
(MAPKpT202), which phosphorylates Bim and targets it for
ubiquitination and degradation52–55. Hence, these differences
could render cluster 2 cells more sensitive to chemotherapy-
induced apoptosis. (Supplementary Tables 14 and 15). See
Supplementary Data 7 for the full list of proteins.






Figure 5 | Histotype-specific immunostains of SOC and OCI xenograft tumours. Formalin-fixed paraffin-embedded sections of xenograft tumours derived
from OCI and SOC lines were stained with ovarian carcinoma histotype-specific markers; PAX8, oestrogen receptor (ER), Wilm’s tumour (WT1), p53, p16,
HNF1b and ARID1a. Nuclear staining (brown) for PAX8, ER, WT1, p53, HNF1b and ARID1a is specific. The occasional cytoplasmic or stromal staining with
these markers is nonspecific. In contrast, tumour-specific p16 staining is typically cytoplasmic. Scale bar, 20mM. See Supplementary Fig. 15 for additional
images.
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We also examined the correlation of the OCI cell lines with
molecular subtypes of ovarian cancer. Two large studies (n¼ 734)
in the US (TCGA) and Australia (AOCS) classified ovarian
cancers based on their molecular profiles56,57. In the TCGA
study, four subgroups were identified: mesenchymal,
differentiated, immunoreactive and proliferative57. In the AOCS
study, six prognostic subgroups were identified (c1–c6)56, with
the additional subtypes being comprised of tumour histotypes not
included in the TCGA study that was restricted to high-grade
serous ovarian cancer. It was found that the TCGA mesenchymal
subtype and AOCS C1 subtypes displayed a significant trend
towards early relapse and short overall survival56,57.
Interestingly, we found that our OCI cluster 1-specific
signature that correlates with poor clinical outcome was nearly
identical to the AOCS C1 (R¼ 0.93) (Fig. 8a,b; Supplementary
Fig. 22) and was most similar to the TCGA mesenchymal subtype
(Fig. 8c,d). These correlations provide support for prognostic
models that validated these signatures58–60. To explore the
possibility that the OCI lines differ in their epithelial/
mesenchymal state, we also compared the OCI mRNA levels
with epithelial–mesenchymal transition core signature profiles61.
We found that cluster 2 OCI samples are characterized by high
levels of epithelial markers and cluster 1 OCI lines high levels of
mesenchymal markers consistent with the above results
(Supplementary Fig. 22).
Discussion
Over the past six decades, the great majority of human cancer
subtypes have proven to be difficult to propagate in cell culture.
This problem derives from the suboptimal conditions of in vitro
culture and culture media that poorly recapitulates the conditions
in living tissue. The resulting panels of cancer cell lines have
hampered many attempts at preclinical drug development, in that
the behaviour of the limited set of available cell lines, both in vitro
and in vivo, are frequently unpredictive of clinical responses.
Here, we present a method for propagating a diverse array of
























































Figure 6 | The OCI lines identify two major outcome groups. (a) Unsupervised hierarchical clustering of gene expression data of 37 cell lines and 285
human tissues reveal three clusters. Genes with Z2-fold expression differences relative to the median value across cell lines and tissues in at least four
samples were selected for hierarchical clustering analysis (3,831 gene features). Rows represent individual genes and columns represent each cell line or
tissue. The red and green colour in cells reflect relative high and low expression levels, respectively, as indicated in the scale bar (log2-transformed scale).
Red and blue bars above the heatmap indicate human tumour samples; light-blue bars indicate OCI lines; and black bars indicate SOC lines. While SOC cell
lines (black bars) are exclusively group within patient cluster P2 (red bar), the OCI cells (light-blue bars) predominantly group within patient cluster
P1 (blue bar). A small subset of tumour samples form a third cluster that does not include any cell lines (white); this group was excluded from outcome
analysis. The complete mRNA expression data set is available at Gene Expression Omnibus, GEO accession number GSE40788 and GSE9899. (b) The
progression-free and overall survival analysis data of patients with the ovarian tumours in patient cluster 1 and 2 in a. The patients with tumours that have a
gene expression profile to OCI lines (blue bar, cluster 1 in a) have worse outcomes than patients with tumours that have gene expression profiles similar to
SOC lines (red bar, cluster 2 in a). The small cluster of tumours that did not include any cell lines (white) was excluded from the outcome analysis.
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form of a novel medium and alterations in oxygen and serum
levels, has yielded to date a panel of 25 new ovarian cancer cell
lines that are extensively characterized, with histopathological
and molecular analyses that includes whole-genome profiles of
DNA and RNA data and protein arrays. In this report, we provide
detailed description of the medium and methods in the
Supplementary Material. In addition, the cell lines described
here are made available to the scientific community as a
renewable resource for basic and translational research. These
new cell lines will nearly double the number of ovarian carcinoma
cell lines available from public repositories.
The molecular profile of OCI cell lines we describe here
demonstrate a remarkable stability over time and consistency
across multiple platforms including their DNA, mRNA and
protein profiles62, and recapitulate clinically relevant patient
populations. For example, there was a remarkable similarity
between mRNA expression signature of poor outcome patient
tumours in the AOCS C1 and TCGA mesenchymal data sets and
our poor outcome cell lines (OCI cluster 1). In addition, we found
that OCI cluster 1 lines have an epithelial–mesenchymal
transition-like signature that has been associated with cancer
stem cells, resistance to chemotherapeutic treatments and
invasion of tumour cell clusters through the mesothelial lining
of the peritoneal cavity—a critical step in the dissemination of
ovarian carcinoma62. These observations lend support for the
potential relevance and utility of OCI cell lines for ovarian cancer
research.
Consistent with these results, we found that OCI lines in
cluster 1 lines are more resistant to taxol and cisplatin, both first-
line treatments for ovarian cancer, compared with SOC/OCI cell
lines in cluster 2. This result provides the beginning of evidence
that the in vitro drug responses of these OCI lines may indeed
correlate closely with in vivo patient responses to drug treatments.









































































































































































































































































































































































































































































Figure 7 | The OCI lines identify two major taxol and cisplatin response groups. (a) Taxol response of OCI and SOC cell lines that are in mRNA/RPPA
cluster 1 versus cluster 2. The OCI and SOC lines were plated in triplicates in OCMI medium (3,000 cells per well) in 96-well plates. The next day, 20 nM
taxol was added and metabolic activity was measured as 590/530 fluorescence via Alamar Blue after 96 h. OCI cell lines in mRNA/RPPA cluster 1, blue
bars; SOC cell lines in cluster 1, red bars; OCI lines in cluster 2, white bars. The results are representative of four different experiments. See Supplementary
Figs 18–20 for further details. (b) Proteins that are differentially expressed in mRNA/RPPA cluster 1. Analysis of RPPA data from OCI and SOC lines
revealed a subset of proteins and phosphor-proteins that are differentially expressed in the taxol-resistant OCI lines (cluster 1, blue labels; cluster 2,
red labels; Po0.05, Student’s t-test). Rows represent cell lines and columns represent antibody probes for each protein. The red and green colours reflect
relative high and low expression levels, respectively. Please see Supplementary Tables 14 and 15 and Supplementary Data 6 for further details.
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patient data is especially encouraging since it has been recognized
that such correlations are rare with standard tumour cell lines,
which tend to be more drug sensitive than human tumours,
leading to false-positive hits in cell culture-based drug screens.
The closer correlation between OCI lines and human ovarian
tumours is perhaps not surprising, since we observed that
cytological, morphological and molecular features of the OCI
lines and their xenograft tumours resembled specific subtypes of
human ovarian cancer, which has not been the case for most SOC
lines.
While the overall correlation between cell line taxol/cisplatin
response and patient outcome is encouraging, long-term
prospective follow-up studies will be required to determine
whether OCI lines will be predictive of patient response.
Currently, the number of cells in our OCI panel is too small to
carry out robust statistical analysis to determine whether there are
42 significant clusters. It is possible that with a larger panel of
cell lines we will discover additional molecular subtypes.
Furthermore, more diverse data sets from human tumours will
be needed for histotype-specific studies, because over 95% of the
nearly 1,500 samples in 12 publically available gene expression
data sets with outcome data are from stage 3–4, high-grade (3)
serous ovarian cancers58,63. The data set that includes non-serous
histotypes contains 8 clear-cell, 13 mucinous and 37 endo-
metrioid cancers; however, no outcome data are available for
these samples18,63. There is a close correlation between form and
function in biology, and the marked differences in tumour
architecture and cell morphology among distinct ovarian cancer
histotypes suggest deeper underlying molecular differences that
are yet to be discovered38.
Regarding mRNA expression subtypes of ovarian cancer, it is
worth pointing out that several of the AOCS/TCGA subcategories
are characterized by immune (c2), stromal (c4) or proliferation
(c5) signatures. As we described, the immune and stromal cells
have to be eliminated from the culture for successful establish-
ment of tumours as cell lines. Otherwise fibroblasts will typically
outgrow the tumour cells. In OCMI medium, the non-tumour
cells are naturally eliminated during the first several passages.
Thus, the OCI cell lines are free of stromal and other cells, and as
a result we did not expect them to replicate tumour subtypes that
are defined by non-tumour signatures such as the c2 and c4
subtypes. While the in vivo proliferation rates of tumours can be
markedly different, such as the c5 subtype, the successful culture
of tumours involves expansion of proliferating cells. Hence, the
in vitro proliferation rate differences are likely to be less
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Figure 8 | The OCI cluster 1 is similar to TCGA and AOCS poor-outcome groups. (a) Pearson correlation values for each of the signature scores indicate a
very strong correlation among the genes that are expressed in the OCI cluster 1 and the Tothill C1 group (R¼0.93). Interestingly, both of these signatures
also exhibit a strong correlation with genes that are abundantly expressed in vascular endothelial cells (40.7)60, suggesting that both of these signatures
define ovarian cancer cells with mesenchymal/endothelial attributes. (b) The Kaplan–Meier overall survival plot of the Tothill C1–C6 groups indicate that
the Tothill C1 group that correlated with OCI cluster 1, has one of the poorest outcomes. (c) The box-and-whisker plots of the signature scores for the TCGA
‘poor prognosis genes’ demonstrate that the TCGA mesenchymal group is most similar to OCI cluster 1 in a statistically significant manner. The two-tailed
t-test was used to compare the mesenchymal group signature score versus the three other groups (P¼0.034). The interquartile range is shown by the box
and the bar within the box represents the median value. (d) The Kaplan–Meier overall survival plot of the 482 TCGA tumours with clinical follow-up
demonstrate that the TCGA mesencyhmal subtype that correlates with the OCI cluster 1 also has one of the worst outcomes. See Supplementary Figs 21
and 22 for further details.
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In conclusion, we describe here the initial instalment of our
efforts as a proof of concept towards establishing a comprehen-
sive ovarian carcinoma cell line panel. Even at this early stage the
results are encouraging, and we are in the process of establishing
additional lines representing each subtype that will be needed to
explore the histotype-specific differences and intra-tumoral
heterogeneity of ovarian tumours.
While we have successfully cultured a number of colon and
lung cancer cells in OCMI medium, we do not recommend this
medium as a universal culture environment for all tumours at this
time. Our experience with other tumour types indicates that to
achieve high success rates and maintain the phenotypic properties
of the original tissue, each tumour type will require tissue-specific
modifications in medium formulation for optimum results.
In the future, a robust and efficient culture system yielding
cancer cell populations that predict patient responses to various
drugs should improve development of new drugs for personalized
treatment of cancer patients. It should also improve the ability to
identify mechanisms of resistance and to develop rational drug
combinations. Our preliminary results suggest that the metho-
dology we describe here can be modified with tissue-specific
changes to culture other tumour types such as leukaemias, as well
as normal breast, ovarian and fallopian tube cells16,18,64. We
foresee that this approach can one day be used for personalized
oncology where the in vitro drug-sensitivity profile of each
patient’s tumour can be assessed real time and this information
can be used to guide treatment decisions.
Methods
Primary tumour culture and cell lines. The OCI cell lines and OCMI medium are
available from the Live Tumor Culture Core at Sylvester Comprehensive Cancer
Center, Miller School of Medicine, University of Miami http://sylvester.org/shared-
resources/Live-Tumor-Culture-Core. To establish the cell lines, fresh tumour tissue
fragments are minced and plated on Primaria (BD Biosciences) plates before and
after digestion with 1 mg ml 1 collagenase (Roche). The tumour cells are cultured
in nutrient medium described previously16, supplemented with insulin,
hydrocortisone, epidermal growth factor (EGF), cholera toxin and serum as
described in Supplementary Methods. We refer to this version of the medium as
OCMI. This formulation is supplemented with 17b-estradiol for endometrioid and
mucinous tumours (OCMIe). The papillary serous, clear-cell, dysgerminoma and
carcinosarcoma tumours are initially cultured in 5% CO2 and regular O2 at 37 C as
monolayers attached to Primaria culture plates. The endometrioid and mucinous
tumours are initially cultured in 5% CO2 and low O2 (5%) at 37 C as monolayers
attached to Primaria culture plates. Adjustments in O2 and plates are made for
individual cell lines as necessary (Supplementary Table 3). The tumour cells are
passaged at a B1:3 ratio once a week and plated into a new flask at B1 104
cells cm 2. During the initial weeks of culture, (B1–5) the plates are treated with
diluted trypsin first, to deplete stromal cells. The remaining cells that are still
attached to the culture plate are treated with 0.25% trypsin for subculturing. In
general, tumour cultures are free of stromal and normal cell types within 4–6
passages. The SOC cell lines were short tandem repeat validated and cultured as per
the instructions of the vendor. OCI lines will be available from the Ince laboratory
upon publication. All study procedures were approved by the Institutional Review
Boards of the University of Miami, Brigham & Women’s and Massachusetts
General Hospitals to collect discarded tissues with written consent from all
patients. See Supplementary Note 1 for further details of culture methods.
Macromolecular analysis. Protein expression was analysed by RPPA, as described
previously65,66. Replicate data were averaged, log2 transformed, median centred
and subjected to hierarchical clustering using the un-centred Pearson correlation in
Cluster (v.3.0) and Java TreeView (v.1.1.1). mRNA expression for the cell lines was
measured using the Illumina HumanHT-12 v4 Expression BeadChip platform67.
The gene expression data for 285 ovarian tumour samples were obtained from
the GEO (accession number: GSE9899) and normalized by the robust multichip
average (RMA) method68. The genomic DNA from tumours and cell lines were
analysed with Affymetrix 250K Sty chips69. The copy-number analysis was
performed using the Molecular Inversion Probe (MIP) 330 k microarrays from
Affymetrix. The details of MIP assay have been previously described70. (See
Supplementary Methods for further details.)
Drug-sensitivity experiments. The relative sensitivities of OCI and SOC cell lines
to chemotherapy drugs was measured by seeding an equal number of cells in six
replicates in 96-well black-walled clear-bottom Corning plates at 3,000 cells per
well, and allowing attachment in OCMI for 12 h. Both OCI and SOC cell lines were
exposed to drugs in OCMI medium. The cell lines were cultured in the presence of
drug or vehicle control for 96 h. The fraction of metabolically active cells after drug
treatment was measured by incubation with 2:10 (v/v) CellTiter-Blue reagent
(Promega Cat# G8081) in media for 2 h, and the reaction was stopped by addition
of 3% SDS. Fluorescence was measured in a SpectraMax M5 plate reader (Mole-
cular Devices, CA) using SoftMax software (555EX/585EM). See Supplementary
Methods for additional details.
Analysis of tumorigenicity. Single-cell suspensions were prepared in a Matrigel:
medium mixture (1:1) and 1–5 million cells per 100ml volume were injected in one
intraperitoneal and two subcutaneous sites per mouse. Tumour cell injections were
performed on 6–8-week-old female immunodeficient nude (Nu/Nu) mice (Charles
River Laboratories International, Inc, Wilmington, MA). Tumours were harvested
5–9 weeks after implantation. Tumour histopathology was assessed with haema-
toxylin and eosin staining of formalin-fixed paraffin-embedded sections. All mouse
studies were approved by the University of Miami, the BWH or MGH Institutional
Animal Care and Use Committee.
Mutational analysis. Mutation detection was carried out at the MD Anderson
Cancer Center Sequencing and Microarray Facility by amplifying purified DNA
with primers designed to amplify coding regions of the p53 gene (exons 5–9).
Primers were designed using a variety of software applications including, but not
limited to, Primer Express v3.0 (Applied Biosystems). The PCR products were
purified with ExoSAP-IT (USB) and sequenced in both directions using BigDye
Terminator chemistry (Applied Biosystems) and run on a 3730 DNA Analyzer
(Applied Biosystems). The sequence data files were aligned and compared with a
reference sequence (from Ensembl TP53: Gene ID ENSG0000014150 Transcript
TP_002 ENST00000445888) in SeqScape v2.5 Software (Applied Biosystems) and
mutations analysed.
Gene and protein expression analysis. Analysis of mRNA and protein expres-
sion profiling data, LOH and DNA copy-number changes are described in the
Supplementary Methods.
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